Tuesday, October 03, 2017 7:31:44 AM
ITUS Corporation (NASDAQ: ITUS) today announced that it has received formal notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC that the company has regained compliance with the minimum bid price requirement of The Nasdaq Stock Market as required for continued listing on The Nasdaq Capital Market. On August 18, 2017, the company was notified by NASDAQ that it no longer met the minimum bid price requirement for continued listing, and the August 18 matter is now closed.
"We are very pleased to be back in compliance with the Nasdaq listing requirements, and are excited about the future development of our Cchek™ early cancer detection platform, as well as the opportunities to expand into cancer therapeutics with CAR-T technology for Ovarian Cancer," stated Dr. Amit Kumar, ITUS Chief Executive Officer.
Recent ANIX News
- Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board • PR Newswire (US) • 04/18/2024 12:20:00 PM
- Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties • PR Newswire (US) • 03/14/2024 12:45:00 PM
- Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress • PR Newswire (US) • 03/11/2024 12:00:00 PM
- Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 02/12/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/08/2024 09:15:32 PM
- Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference • PR Newswire (US) • 01/29/2024 01:50:00 PM
- Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology • PR Newswire (US) • 01/23/2024 12:55:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:08:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:07:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:07:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:05:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:05:16 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/16/2024 10:29:43 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/16/2024 09:43:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/16/2024 09:30:49 PM
- Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024 • PR Newswire (US) • 01/10/2024 02:00:00 PM
- Anixa Biosciences to Present at Biotech Showcase 2024 • PR Newswire (US) • 12/14/2023 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 11:01:47 AM
- Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine • PR Newswire (US) • 12/06/2023 11:00:00 PM
- Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine • PR Newswire (US) • 12/06/2023 09:05:00 PM
- Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology • PR Newswire (US) • 11/27/2023 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/02/2023 02:58:20 PM
- Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference • PR Newswire (US) • 10/31/2023 12:30:00 PM
- Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board • PR Newswire (US) • 10/23/2023 12:30:00 PM
- Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 10/13/2023 12:30:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM